Elvanse Prescribing in the UK: Shared Care, GP Roles & Controlled Drug Rules
Elvanse (lisdexamfetamine) is a first-line stimulant for ADHD in the UK, but its prescribing is tightly regulated: it must be initiated by a specialist, is classified as a Schedule 2 controlled drug, and is usually transferred to GP prescribing only under a formal shared care agreement once the dose is stable. Understanding how shared care works, what GPs can and cannot do, and the controlled drug rules helps patients navigate treatment smoothly and avoid gaps in medication.
What Is Elvanse and Who Can Prescribe It?
Elvanse (lisdexamfetamine) is licensed in the UK for:
Children and adolescents aged 6–17 years when response to methylphenidate is clinically inadequate, and
Adults with ADHD as part of a comprehensive treatment programme.
Crucially, all ADHD medication must be initiated by a healthcare professional with training and expertise in diagnosing and managing ADHD (e.g., consultant psychiatrist, community paediatrician, or other specialist within an ADHD service). GPs should not start or titrate Elvanse de novo.
After titration and dose stabilisation, NICE guidance recommends that prescribing and ongoing monitoring should be carried out under Shared Care Protocol arrangements with primary care, where appropriate.
Shared Care Agreements: The Backbone of Safe ADHD Prescribing
What is a Shared Care Agreement (SCA)?
A Shared Care Agreement (also called a Shared Care Protocol) is a formal arrangement between:
The specialist service (e.g., community paediatrics or adult ADHD clinic),
The GP practice, and
The patient (and parents/carers for children).
It sets out who is responsible for diagnosis, initiation, dose changes, prescribing, and monitoring at each stage of treatment.
SCAs exist to:
Ensure safe, consistent prescribing across settings,
Reduce duplication and gaps in monitoring,
Clarify lines of communication and responsibility,
Support equitable access to ADHD medication on the NHS.
When does shared care start?
Typically, shared care is considered only after:
The diagnosis has been confirmed by an appropriate specialist,
Elvanse has been initiated and the dose titrated and stabilised (often over at least 3 months),
The patient has been on a stable dose with satisfactory monitoring (e.g., blood pressure, pulse, weight, and where relevant height) for at least 4 weeks, and
The specialist has written to the GP requesting shared care and confirming the ongoing dose and monitoring plan.c
“Stable” generally means:
Consistent symptom control on the same dose,
Side effects that are absent or manageable,
No planned dose changes in the near term.
Are GPs obliged to accept shared care?
No. A shared care agreement is a professional courtesy, not a legal obligation. GPs may decline if they:
Are not confident managing the condition or medication,
Have concerns about monitoring capacity or workload,
Are unsure about the quality or source of the original assessment (especially with some private providers).
If a GP declines, the specialist service remains responsible for prescribing and monitoring, or the patient may need to continue private prescribing if the assessment was done privately.
Specialist vs GP Responsibilities Under Shared Care
While local protocols vary, most SCAs for Elvanse follow a similar division of responsibilities.
Specialist responsibilities
The specialist service (consultant-led ADHD clinic or community paediatrics) typically:
Confirms the ADHD diagnosis using recognised criteria (e.g., DSM-5) and collateral information from school/work/family.
Confirms that first-line options (e.g., methylphenidate in children) have been tried and were inadequate or not tolerated, where relevant.
Performs baseline monitoring before starting Elvanse:
Blood pressure and pulse,
Weight (and height in children/adolescents),
Relevant history (cardiac, psychiatric, substance use).cheshireandmerseysideformulary+1
Initiates treatment and prescribes an initial trial period (often 1 month) to assess response and tolerability.
Titration and dose optimisation over the first weeks to months, reviewing the patient regularly (e.g., at 4–6 weeks, then every 3–6 months once stable).
Undertakes ongoing specialist monitoring (e.g., at least every 6 months in children, annually in adults, or as locally agreed), including:
Blood pressure, pulse, weight, and height (in under-18s),
Review of efficacy, side effects, and comorbidities.
Communicates clearly with the GP:
Diagnosis and assessment summary,
Starting dose and titration plan,
Stable dose and ongoing monitoring requirements,
Any changes to treatment or concerns.
Requests the GP’s agreement to enter shared care once the patient is stable.
GP responsibilities (once shared care is accepted)
Once the GP accepts shared care, they typically:
Provide monthly repeat prescriptions of Elvanse at the dose specified by the specialist.
Ensure prescriptions comply with controlled drug rules (see below).
Monitor and record at least annually (or as per local protocol):
Blood pressure and pulse,
Weight (and height in children/adolescents),
Review of side effects, adherence, and any new medical or psychiatric issues.
Report any significant adverse effects, concerns about misuse/diversion, or loss of response back to the specialist promptly.
Do not initiate, stop, or change the dose of Elvanse without specialist advice. Any dose adjustments should be directed by the specialist service.
Participate in periodic review of the shared care arrangement, especially if the patient’s circumstances change (e.g., pregnancy, new cardiac history, substance misuse).
Patients should allow sufficient time (often at least 48–72 hours) for repeat prescriptions to be processed, as controlled drug prescriptions require extra checks.
Elvanse as a Controlled Drug: Key UK Rules
Lisdexamfetamine is classified as a Schedule 2 controlled drug under the Misuse of Drugs Regulations 2001. This brings specific legal requirements for prescribing, dispensing, and record-keeping.
Prescription validity and supply limits
For Schedule 2 controlled drugs like Elvanse:
Prescriptions are valid for only 28 days from the date on the prescription. After 28 days, they cannot be dispensed.
Prescriptions should be for a maximum of 30 days’ supply. Monthly prescribing is standard for ADHD stimulants.
Prescriptions must include:
Patient name and address,
Drug name, formulation, and strength,
Dose and directions,
Total quantity in both words and figures,
Prescriber’s signature and date.
GPs and specialists must follow these rules strictly; pharmacies will reject non-compliant prescriptions.
Safe custody and record-keeping
In secondary care and some primary care settings:
Controlled drugs must be stored securely (e.g., in a locked controlled drugs cupboard).
Practices and clinics must maintain controlled drug registers and follow local governance arrangements for auditing and reconciling stock.
For patients:
Elvanse should be stored safely at home, out of reach of others, and never shared. Diversion or supply to others is illegal.
Travel and possession
Patients travelling abroad with Elvanse may need:
A letter from their prescriber confirming the medication and dose,
In some cases, a personal licence from the Home Office if travelling for more than 3 months or to certain countries.
Patients should check destination-country rules well in advance.
How Shared Care Works in Practice: A Typical Pathway
While local pathways differ, a common NHS route looks like this:
Referral and assessment
GP, school, or self-referral (depending on local pathway) to an ADHD service.
Specialist assessment using DSM-5 criteria, with collateral information from family, school, or work.
Diagnosis and treatment planning
Diagnosis confirmed and discussed with the patient (and parents/carers for children).
Non-pharmacological support offered (e.g., psychoeducation, environmental adjustments).
Medication options discussed; for many, methylphenidate is tried first in children, while adults may be offered lisdexamfetamine or methylphenidate first-line depending on local policy and NICE guidance.
Initiation and titration in secondary/specialist care
Specialist initiates Elvanse (often after inadequate response to methylphenidate in children).
Prescribes an initial 1-month trial, then reviews at 4–6 weeks.
Dose is adjusted in 10–20 mg steps at roughly weekly intervals until an optimal dose is reached (up to 70 mg/day).
Stabilisation period
Patient remains on a stable dose for at least 2–3 months with consistent benefit and tolerable side effects.
Monitoring (BP, pulse, weight, and height where relevant) is satisfactory.
Shared care request to GP
Specialist writes to the GP with:
Diagnosis summary,
Current dose and formulation,
Monitoring results and plan,
Request to enter shared care.
GP reviews and decides whether to accept shared care.
Ongoing primary care prescribing and monitoring
GP issues monthly repeat prescriptions under controlled drug rules.
GP monitors at least annually (or per local protocol) and liaises with the specialist if issues arise.
Specialist reviews at least every 6–12 months, or sooner if needed.
If shared care breaks down (e.g., GP declines, monitoring lapses, or concerns about misuse), the specialist may reclaim full prescribing responsibility or refer the patient back for further review.
Private ADHD Assessments and Shared Care
Private ADHD assessments are increasingly common, but shared care with NHS GPs is not automatic.
Many GP practices will only consider shared care if:
The assessment was conducted by a suitably qualified specialist (e.g., consultant psychiatrist) with expertise in ADHD,
The assessment followed UK diagnostic standards and included comprehensive history and collateral information,
There is clear documentation of diagnosis, dose titration, stability, and monitoring,
The request for shared care comes directly from the specialist, not just the patient.
Some practices have policies that they will only enter shared care with NHS specialist services, not private clinics. In such cases, patients may need to continue private prescribing or seek an NHS assessment.
Patients considering private assessment should check their GP’s policy in advance to avoid unexpected costs or gaps in medication.
Frequently Asked Questions (FAQs)
1. Can my GP start me on Elvanse without a specialist assessment?
No. UK guidance states that all ADHD medication must be initiated by a healthcare professional with expertise in ADHD. GPs should not start or titrate Elvanse without specialist involvement.
2. What is a shared care agreement and do I need one?
A shared care agreement is a formal arrangement between your specialist, GP, and you, setting out who prescribes and monitors your ADHD medication. It is not legally required but is strongly recommended by NICE once your dose is stable, to enable convenient NHS prescribing and monitoring in primary care.
3. Can my GP refuse to sign a shared care agreement?
Yes. Shared care is a professional courtesy, not an obligation. GPs can decline if they are not confident managing your treatment or if they have concerns about the assessment or monitoring arrangements. In that case, the specialist remains responsible for prescribing, or you may need private prescribing.
4. How often can my Elvanse prescription be issued?
Elvanse is a Schedule 2 controlled drug. Prescriptions are usually for a maximum of 30 days’ supply and are valid for only 28 days from the date on the prescription. Monthly repeat prescriptions are standard.
5. Can my GP change my Elvanse dose?
Under most shared care agreements, GPs should not initiate, stop, or change the dose of Elvanse without specialist advice. Any dose adjustments should be directed by the specialist service, who will then inform the GP of the new dose.
6. What monitoring do I need while on Elvanse?
Typical monitoring includes:
Blood pressure and pulse,
Weight (and height in children/adolescents),
Review of side effects, mental health, and adherence.
This is done at least annually in primary care and more frequently in specialist care, especially during titration.
7. I had a private ADHD assessment. Will my NHS GP prescribe Elvanse?
Not necessarily. Many GPs will only enter shared care with NHS specialist services or with private specialists who meet strict criteria. Check your GP’s policy before pursuing a private assessment to avoid unexpected costs or gaps in prescribing.
Book an ADHD Assessment with a UK Specialist Service
If you suspect you or your child may have ADHD, or if you’re struggling to access or maintain treatment under shared care, a thorough specialist assessment is the essential first step.
Focus Gently provides comprehensive ADHD assessments for children, teens, and adults, including:
Detailed clinical interviews exploring developmental history and current functioning
Standardised rating scales and collateral information from family, school, or work where appropriate
Clear diagnostic feedback aligned with UK criteria
Personalised treatment recommendations, including guidance on medication options such as Elvanse and support with shared care planning
A robust, specialist-led assessment not only clarifies diagnosis but also strengthens the foundation for safe, effective long-term prescribing and monitoring.
